IQ EQ Fund Management
PMCB icon

IQ EQ Fund Management’s PharmaCyte Biotech PMCB Stock Holding History

IQ EQ Fund Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,147
Closed -$120K – 244
2022
Q4 		$120K Buy
2,147
+106
+5% +$5.77K 0.02% 223
2022
Q3 		$93K Buy
+2,041
New +$98.1K 0.02% 205

Other funds holding PMCB

Ayrton Capital
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.2B AUM 6.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Equitec Proprietary Markets
Equitec Proprietary Markets Chicago, Illinois $400M AUM 66.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

IQ EQ Fund Management's PMCB Position: Q1 2023 in Review

IQ EQ Fund Management sold out of PharmaCyte Biotech (PMCB) in Q1 2023, closing a stake of 2,147 shares — an estimated $120K sold.

IQ EQ Fund Management first reported a position in PMCB in Q3 2022 and held it in 2 quarters. The position peaked at $120K in Q4 2022. 26 funds tracked by Wall St. Rank hold PMCB as of Q1 2023.

  • IQ EQ Fund Management reported no remaining PharmaCyte Biotech position as of Q1 2023 after selling out during the quarter.
  • IQ EQ Fund Management sold 2,147 PharmaCyte Biotech shares in Q1 2023, an estimated $120K.
  • IQ EQ Fund Management first reported a position in PharmaCyte Biotech in Q3 2022 and held it in 2 quarters.
  • IQ EQ Fund Management's PharmaCyte Biotech position peaked at $120K in Q4 2022.
  • 26 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2023.

Based on IQ EQ Fund Management's 13F filing for Q1 2023, filed 10 May 2023.